Enhanced Front Line Therapy for NDMM: Promising Results from the MajesTEC-7 Trial
June 4th 2024Results from the initial safety run-in of MajesTEC-7 indicate that the combination of teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma (NDMM) shows a manageable safety profile with early signs of efficacy.
Watch